Should paradoxical psoriasis trigger rheumatological surveillance during interleukin (IL)-4/IL-13 blockade?
Clinical and Experimental Dermatology · 24.07.2026
DOI: 10.1093/ced/llag330 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 24.07.2026. Verfasst von Ercan Yılmaz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Inonu University, Faculty of Medicine, Pediatric Allergy and Immunology Department, Malatya, Turkey. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Lauletta et al. (Clin Exp Dermatol 2026; 51:612–19) provide important real-world evidence on paradoxical psoriasis and seronegative spondyloarthropathy during interleukin (IL)-4/IL-13 blockade in atopic dermatitis. However, an important unanswered question is whether paradoxical psoriasis represents an early clinical marker of subsequent inflammatory arthritis rather than an isolated adverse event. Clarifying this relationship could inform targeted musculoskeletal surveillance and improve early diagnosis and long-term outcomes.
Autor:innen und Institutionen
- Inonu University, Faculty of Medicine, Pediatric Allergy and Immunology Department, Malatya, Turkey.
Zitieren
APA
Yılmaz, E., Özer, N. K., & Topal, E. (2026). Should paradoxical psoriasis trigger rheumatological surveillance during interleukin (IL)-4/IL-13 blockade?. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag330
Vancouver
Yılmaz E, Özer NK, Topal E. Should paradoxical psoriasis trigger rheumatological surveillance during interleukin (IL)-4/IL-13 blockade?. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag330
BibTeX
@article{Ylmaz2026,
author = {Yılmaz, Ercan and Özer, Nezihe Koker and Topal, Erdem},
title = {Should paradoxical psoriasis trigger rheumatological surveillance during interleukin (IL)-4/IL-13 blockade?},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llag330}
}
EUVIMED